Enliven Therapeutics (ELVN)

• Market cap: $1.27B
• 1 day: -0.28%
• 5 days: 4.73%
• 1 month: 5.86%
• 3 months: 7.08%
• 6 months: 15.23%
• Year to date: -10.08%
• 1 year: -24.65%
• 5 years: -67.71%
• 10 years: -64.18%
• Sector: Healthcare
• Industry: Biotechnology

About: Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Employees: 63